The University of Aberdeen, led by Zosia Miedzybrodzka, cares for Huntington’s disease (HD) patients, such as Sandy Patience of Scotland, as the 801 patient global study known as Generation-HD1 unfolds. Patience inherited this condition and declared the clinical...
Amgen’s AMG 510, the first therapy to reach clinical trials that inhibits a mutant KRAS protein, has demonstrated promising safety and efficacy results based on preliminary animal studies and clinical trials ongoing. It is now entering Phase II clinical trials. It got...
Stanford University researchers study concludes that clinical trials can offer patients with Huntington’s disease (HD) hope when there are no treatments available despite unknowns whether the therapy will work or is safe. The study results show that although the HD...
Kaiser Permanente, one of the nation’s largest health systems, conducted a real-world study to find that neurological side effects from phenytoin, an anti-seizure medication, are more common in patients with certain genetic variants. Interestingly, the same genetic...
Thermo Fisher Scientific’s new gene editing tool will help researchers find therapies for cancer and other diseases. Called the Invitrogen LentiArray CRISPR Libraries, it is a ready-to-use array of knockout libraries for the human genome. The library suite offers...
The University of British Columbia (UBC), BC Children’s Hospital, and an international team of investigators published in the New England Journal of Medicine a rarely-seen type of DNA mutation as the potential cause of an inherited metabolic disorder. Often the result...
